Webcast to discuss data presented at ESMO Plenary Session
Filed with ASX · · 15 pages · English
Summary by 6ix AI
The presentation highlights the complementary effects of Efti with KEYTRUDA and reports on the trial's design, patient demographics, and treatment outcomes. Key findings include a significant tumor response rate and a strong safety profile, indicating promising results for a chemo-free regimen in this patient population. The company outlines future milestones and catalysts, including updates on various cancer studies and a solid cash balance to support ongoing operations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Immutep
- Positive results in TACTI-003 for 1L HNSCC cohort B patients
- Webcast slides for new Efti clinical data in 1st line HNSCC
- Positive topline results from ph2b in head & neck cancer
- Immutep completes underwritten retail entitlement offer
- Immutep completes institutional pro-rata offer & placement
Later from Immutep
- Regulatory Clearance received for Phase 1 trial of IMP761
- Successful Meeting with FDA on Phase III Design in NSCLC
- First Participant Dosed in Phase I Study of IMP761
- TACTI-003 data selected for oral presentation at ESMO 2024
- Appendix 4E & 2024 Full Year Statutory Accounts
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep